Business Wire

Leapmotor unveils its entire new product line at the Shanghai International Auto Show

19.4.2023 09:32:00 CEST | Business Wire | Press Release

Share

On April 18th, the 20th Shanghai International Auto Show officially kicked off, and Leapmotor (Zhejiang Leapmotor Technology Co Ltd, HKG: 9863) brought its entire new product line to the event, including the C11 extended range model, the 2023 C01, C11, and T03. Leapmotor Chairman Zhu Jiangming, along with other executives, transformed into "super test drivers" and personally drove the cars to give users a close-up experience of the company's commitment to being an "OEM for the users."

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418006053/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

Leapmotor's entire new product line with their value propositions, making car selection and purchase less of a hassle.

The C11 extended range model boasts a 285km pure electric range leading in its class, with a maximum comprehensive range of 1024km, a 2930mm extra-long wheelbase, and features such as an immersive triple-screen display, Nappa leather seats, frameless doors, and a premium quality music cockpit, all of which elevate the luxurious experience. In addition, the C11 extended range model is equipped with 28 perception hardware devices, with as many as 23 driving assistance functions launched at once, allowing users to calmly handle complex driving scenarios such as city and high-speed driving over long distance.

The 2023 C01 model is equipped with the CTC battery-chassis integration technology, with a maximum comprehensive range of 717km under CLTC. The C01 has a maximum power of 400kW and a maximum torque of 720N·m, with hidden door handles, a sleek body, and dynamic tail lights that create a super-low drag coefficient that leads its class. It achieves acceleration from 0 to 100km/h in just over 3 seconds, providing users with an ultimate driving experience.

The 2023 C11 model's intelligent cockpit is equipped with a Qualcomm Snapdragon SA8155P chip, an immersive triple-screen display, and a highly integrated full-touch-control design that provides a smooth experience and supports AI face recognition and other functions. The C11 uses variable architecture high-performance oil-cooled electric drive, with a 0 to 100km/h acceleration time in just 3.94 seconds. The double-wishbone front and 5-link rear independent suspensions comparable to luxury cars greatly improve the handling quality and driving experience of the entire vehicle, while also balancing comfort and handling performance.

The 2023 Leapmotor T03 is positioned as an ultra-safe 5-door electric vehicle, with a 5-door 4-seat, 2400mm long wheelbase design, and a cage-like body with a high-strength steel ratio of up to 68%. It also has up to 10 automatic driving assistance functions, providing double protection for safe driving. In addition, the T03 has passed the EU’s Small Whole Vehicle Type Approval (SWVTA), and Leapmotor will continue to expand its overseas market, further accelerating its global strategic layout.

Chairman serves as “Super Test Driver” and personally drives the guests

The booth layout was inspired by hand-drawn sketches from Leapmotor's founder chairman Zhu Jiangming. In addition to providing free coffee, lunch, fruit, and other services, Zhu Jiangming also held a lunch meeting with the media and users to exchange insights on Leapmotor's car-making, product planning, user needs, and driving experiences in a relaxed chat.

Moreover, Leapmotor also held the “Super Test Driver” event at this year’s auto show, where Zhu and other executives personally drove and chauffeured users, making it more convenient for their attendance.

Leapmotor, beyond your expectation.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tammy Hu
Email: Gmail:Leapmotorglobal@gmail.com
+86 15068893526

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye